Key Points 95% of patients with differentiated papillary or follicular thyroid cancer (DTC) and 4550% of those with medullary thyroid cancer (MTC) survive in the long term However, the probability that these patients will experience tumour recurrence, even after several years in clinical remission, is not negligible Detectable levels of serum thyroglobulin are indicative of persistent or recurrent DTC Thyroglobulin stimulation with exogenous recombinant human TSH is preferable to withdrawal of suppressive levothyroxine therapy, as the latter approach can cause hypothyroidism, which severely affects patients' quality of life The same laboratory, and possibly the same thyroglobulin assay, should be used for the follow-up of a patient with DTC, to account for variations in assay specificity and sensitivity Calcitonin is the most reliable tumour marker for diagnosis and follow-up of MTC
Depression and anxiety can make it feel impossible to stay active and eat a balanced diet
Full AI Image Prompt: Create a clean medical infographic titled GHK-Cu Claim Strength Matrix. Use a two-axis matrix with the horizontal axis labeled Evidence strength and the vertical axis labeled Claim scope. Place labeled cards: Topical skin aging, Wound-care context, Hair growth, Injectable regeneration, and Systemic anti-aging. Position topical skin aging and wound-care context closer to stronger evidence, hair growth in a limited or indirect evidence area, and injectable regeneration and systemic anti-aging in an uncertain evidence-gap area
Note that it may not be recommended for those with specific medical histories, such as medullary thyroid cancer or pancreatitis